Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3.
about
Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor CellsIn vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administrationNatural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsisPostoperative Regulatory T-Cells and Natural Killer Cells in Stage I Nonsmall Cell Lung Cancer Underwent Video-assisted Thoracoscopic Lobectomy or ThoracotomyExpression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Immunological dysregulation in multiple myeloma microenvironment.α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology.Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.T-cell subsets in autologous and allogeneic peripheral blood stem cell concentrates.Regulatory T cells in chronic lymphocytic leukemia: some progress and a bit of "tolerance" in understanding disease progression.An attempt to induce an immunomodulatory effect in rowers with spirulina extract.CD4 T cells react to local increase of α-synuclein in a pathology-associated variant-dependent manner and modify brain microglia in absence of brain pathology.Preliminary investigation on the abnormal mechanism of CD4FOXP3CD25 regulatory T cells in pediatric B-cell acute lymphoblastic leukemia
P2860
Q28083973-11F421B2-DA46-4823-A494-F1A6DD4567DBQ28732675-9DAC288E-5A2F-4408-90E6-617A1854973AQ33754724-8239585B-62A2-451D-B2C4-BCC62877DC88Q34302328-FD5D7526-2E54-4935-AD9C-58A183B1D637Q36523315-0E83F5AA-8335-4310-B7F7-BB928B10182DQ37659012-9A9AF139-543E-40DB-8EB1-C8AD9134DC3AQ38008379-222C62A1-BFF6-4B7B-BDFA-C46E6E12160BQ38228353-EA12A6A2-7C72-436A-9044-26CB337C03F2Q39972820-EB1BAED0-4B39-45F0-B832-4F6DD8462E7FQ40475503-F22A6B38-822B-40EB-AA08-45ED567FE77CQ40871937-E242E245-4B2A-4509-A873-A10A7A466337Q46511243-D6389DBB-5FCF-4747-81B3-E99B40D3E141Q50320917-C3EF0BC5-0652-4DA2-A674-E73A0A82542EQ55546710-264C6DBB-AD26-4644-8297-AB1CE4431EE8Q56890609-21D72480-3489-42D9-ACE2-640F997F801C
P2860
Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparative approach to define ...... assessment of CD127 and FOXP3.
@ast
Comparative approach to define ...... assessment of CD127 and FOXP3.
@en
type
label
Comparative approach to define ...... assessment of CD127 and FOXP3.
@ast
Comparative approach to define ...... assessment of CD127 and FOXP3.
@en
prefLabel
Comparative approach to define ...... assessment of CD127 and FOXP3.
@ast
Comparative approach to define ...... assessment of CD127 and FOXP3.
@en
P2093
P2860
P356
P1476
Comparative approach to define ...... assessment of CD127 and FOXP3.
@en
P2093
Elmar Endl
Marc Beyer
Martin R Weihrauch
Matthias Kochanek
Sabine Classen
Svenja Debey-Pascher
P2860
P304
P356
10.1155/2011/734036
P577
2011-08-28T00:00:00Z